DataMeds AI, Inc.
DataMeds AI, Inc. is a U.S.-based healthcare technology and pharmaceutical distribution company operating through the Wellgistics Health platform. Its activities combine pharmaceutical distribution, prescription routing, pharmacy fulfillment, telepharmacy, and software products such as the EinsteinRx AI pharmacy hub and PharmacyChain blockchain-enabled infrastructure.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaWholesale distribution of prescription drugs and related fulfillment services for pharmacy channels.
EinsteinRx and related digital tools support prescription routing, pharmacy optimization, and patient affordability programs.
Pharmacy operations, delivery coordination, and direct-to-patient prescription fulfillment.
Telepharmacy access, patient services, and partner-enabled healthcare delivery capabilities.
Contract pharmacy, medication access, and related services for qualified healthcare programs.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products93,7 %
- Pharmacy Retail Sales3,7 %
- Third Party Logistics Services2,6 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company serves pharmacies, pharmacy networks, healthcare providers, pharmaceutical manufacturers, and patients receiving prescription medications. Pharmacies and healthcare organizations use its distribution, routing, fulfillment, and telepharmacy capabilities to improve medication access and operational efficiency. Manufacturers and brand partners can use the platform to support product commercialization, while patients benefit from lower out-of-pocket costs and direct fulfillment options.
Purchase pharmaceutical inventory and use routing, delivery, and dispensing-support capabilities.
Use EinsteinRx, PharmacyChain, and related infrastructure to coordinate prescription fulfillment at scale.
Use distribution and commercialization channels to reach pharmacies and patients with prescription products.
Use telepharmacy, direct-to-patient, and medication-access services for distributed care delivery.
Receive prescription drugs, affordability support, and direct fulfillment through participating programs.
Strategia
The company is developing an integrated model that links pharmaceutical distribution with pharmacy software, AI-enabled dispensing optimization, and direct-to-patient services. Current priorities include commercializing EinsteinRx, expanding Wellgistics Pharmacy, integrating PharmacyChain capabilities, and using partnerships such as Kare Pharmtech to broaden patient access. This strategy is intended to increase the value of the platform beyond wholesale drug transactions by connecting manufacturers, pharmacies, providers, and patients.
AI-enabled routing and affordability tools can differentiate the company from traditional distributors.
Owned or closely integrated fulfillment can capture more value across the medication-delivery chain.
PharmacyChain is intended to improve data coordination and support additional healthcare platform services.
Partner distribution can add patient access and service capabilities without relying solely on internal infrastructure.
Maantiede
DataMeds AI is headquartered and principally operated in the United States, with the reported business focused on the U.S. pharmaceutical and pharmacy market. Its activities depend on domestic pharmacy distribution, patient fulfillment, telepharmacy access, and U.S. healthcare-program relationships. The available reports do not provide a country-level or regional revenue breakdown.
Riskit
The business combines regulated pharmaceutical distribution with early-stage healthcare software and patient services, creating execution, compliance, and technology-adoption risks. Liquidity needs were specifically identified as an ongoing risk, while drug pricing, reimbursement, supply availability, cybersecurity, and partner performance can affect demand and operating results. Commercial initiatives such as Brenzavvy, EinsteinRx, and new pharmacy services may not achieve expected adoption or scale.
The company has identified ongoing liquidity needs, which can limit inventory purchases, technology investment, and operating flexibility.
Kohdistuu: Working capital and growth funding
Pharmacy and patient economics depend on drug pricing, payer policies, and affordability programs.
Kohdistuu: Distribution and patient-access activities
Drug distribution, pharmacy operations, controlled substances, 340B programs, and health data are heavily regulated.
Kohdistuu: U.S. pharmaceutical and healthcare operations
EinsteinRx and PharmacyChain require reliable integrations, customer adoption, and successful commercialization.
Kohdistuu: Software and platform expansion
Prescription routing and pharmacy platforms process sensitive healthcare and patient information.
Kohdistuu: AI pharmacy hub and digital infrastructure
Telepharmacy, delivery, and healthcare expansion rely partly on third-party or joint-venture capabilities.
Kohdistuu: Kare Pharmtech and other commercial relationships
Kirjanpito
Harkinnanvaraiset erätPrincipal-versus-agent judgments determine whether sales are reported gross or net and when delivery obligations are satisfied.
Vaikutus: Reported revenue, cost of sales, and margins
Drug expiration, purchase costs, rebates, returns, chargebacks, and pricing adjustments can require reserves or write-downs.
Vaikutus: Inventory, cost of sales, and working capital
Pharmacy and healthcare counterparties may have different payment profiles, making collectability important to cash conversion.
Vaikutus: Accounts receivable and operating cash flow
EinsteinRx and PharmacyChain development or licensing costs may be capitalized subject to eligibility, useful-life, and impairment judgments.
Vaikutus: Intangible assets, amortization, and impairment expense
The Kare Pharmtech relationship and other partnerships may require judgments about consolidation, equity-method treatment, or contractual revenue.
Vaikutus: Revenue, investments, assets, and earnings presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
GridAI Technologies Corp.
GRDX · Electric & Other Services Combined
POMDOCTOR Ltd
POM · Retail-Miscellaneous Retail
POMDOCTOR Ltd is a China-based digital healthcare company built around an internet hospital platform, physician network, and pharmaceutical supply chain operations.
MedWellAI, Inc.
MWAI · Finance Services
HeartSciences Inc.
HSCS · Finance Services
Adapti, Inc.
ADTI · Services-Amusement & Recreation Services
BGM Group Ltd.
BGM · Pharmaceutical Preparations
BGM Group Ltd is a Cayman Islands holding company with operating businesses primarily conducted through subsidiaries and variable interest entities in mainland China.
Päivitetty: 24.9.2026